LT2379586T - Auglio audinius ardantys adenovirusiniai vektoriai ir su jais susiję būdai ir panaudojimas - Google Patents
Auglio audinius ardantys adenovirusiniai vektoriai ir su jais susiję būdai ir panaudojimasInfo
- Publication number
- LT2379586T LT2379586T LTEP09796016.5T LT09796016T LT2379586T LT 2379586 T LT2379586 T LT 2379586T LT 09796016 T LT09796016 T LT 09796016T LT 2379586 T LT2379586 T LT 2379586T
- Authority
- LT
- Lithuania
- Prior art keywords
- methods
- adenoviral vectors
- uses related
- oncolytic adenoviral
- oncolytic
- Prior art date
Links
- 230000000174 oncolytic effect Effects 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20080671A FI20080671A0 (fi) | 2008-12-22 | 2008-12-22 | Onkolyyttiset virukset |
| FI20095466A FI121508B (fi) | 2008-12-22 | 2009-04-27 | Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä |
| US58597109A | 2009-09-29 | 2009-09-29 | |
| PCT/FI2009/051025 WO2010072900A1 (en) | 2008-12-22 | 2009-12-21 | Oncolytic adenoviral vectors and methods and uses related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2379586T true LT2379586T (lt) | 2017-03-10 |
Family
ID=44502296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP09796016.5T LT2379586T (lt) | 2008-12-22 | 2009-12-21 | Auglio audinius ardantys adenovirusiniai vektoriai ir su jais susiję būdai ir panaudojimas |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP2379586B1 (enExample) |
| JP (2) | JP2012513209A (enExample) |
| KR (1) | KR101761094B1 (enExample) |
| CN (1) | CN102264760B (enExample) |
| AU (1) | AU2009332883B2 (enExample) |
| BR (1) | BRPI0924123B8 (enExample) |
| CA (1) | CA2748180C (enExample) |
| CY (1) | CY1120039T1 (enExample) |
| DK (1) | DK2379586T3 (enExample) |
| ES (1) | ES2612889T3 (enExample) |
| HR (1) | HRP20170165T1 (enExample) |
| HU (1) | HUE031689T2 (enExample) |
| LT (1) | LT2379586T (enExample) |
| PL (1) | PL2379586T3 (enExample) |
| PT (1) | PT2379586T (enExample) |
| RU (1) | RU2520823C2 (enExample) |
| SG (1) | SG173432A1 (enExample) |
| SI (1) | SI2379586T1 (enExample) |
| WO (1) | WO2010072900A1 (enExample) |
| ZA (1) | ZA201104224B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011070440A2 (en) | 2009-12-10 | 2011-06-16 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| BR112013006699A2 (pt) * | 2010-09-24 | 2016-06-14 | Oncos Therapeutics Oy | vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral |
| EP2619224A1 (en) * | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| DK2806883T3 (da) | 2012-01-25 | 2019-07-22 | Dnatrix Inc | Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation |
| JP2016513115A (ja) | 2013-02-21 | 2016-05-12 | チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド | ワクチン組成物 |
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| US12421502B2 (en) | 2013-04-18 | 2025-09-23 | Tilt Biotherapeutics Oy | Enhanced adoptive cell therapy |
| DK3461491T3 (da) | 2013-04-18 | 2025-02-03 | Tilt Biotherapeutics Oy | Forbedret adoptiv celleterapi |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| PL3198009T3 (pl) | 2014-09-24 | 2022-01-24 | Salk Institute For Biological Studies | Onkolityczne wirusy nowotworowe i sposoby zastosowania |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
| FI127460B (en) | 2016-01-15 | 2018-06-29 | Targovax Oy | Combining adenovirus and chemotherapeutic agents for treating cancer |
| JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| ES3041500T3 (en) | 2016-03-10 | 2025-11-12 | Cg Oncology Inc | Methods of treating solid tumors by combination therapy |
| LT3293201T (lt) | 2016-09-12 | 2021-03-25 | Targovax Oy | Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui |
| US20190275092A1 (en) * | 2016-11-01 | 2019-09-12 | Dnatrix, Inc. | Combination therapy for treatment of brain cancers |
| WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| AU2018206304A1 (en) * | 2017-01-06 | 2019-07-04 | Stabilitech Biopharma Ltd | Virus |
| EP4599893A3 (en) | 2017-04-14 | 2025-11-05 | CG Oncology, Inc. | Cg0070 for treating bcg resistant bladder carcinoma in situ |
| JP7260173B2 (ja) | 2017-04-21 | 2023-04-18 | ベイラー カレッジ オブ メディスン | 腫瘍溶解性ウイルス療法および免疫療法 |
| BR112019024656A2 (pt) | 2017-05-25 | 2020-06-09 | Univ Central Florida Res Found Inc | vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais |
| WO2019093435A1 (ja) * | 2017-11-08 | 2019-05-16 | 国立大学法人 鹿児島大学 | 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療） |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| JP7430395B2 (ja) | 2018-04-09 | 2024-02-13 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 複製特質が増強された腫瘍溶解性アデノウイルス組成物 |
| EP3725323A1 (en) | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| EP3725888A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase |
| EP3725322A1 (en) | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing granzyme and perforin |
| KR102601875B1 (ko) * | 2020-03-25 | 2023-11-14 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
| CN111909962A (zh) * | 2020-07-23 | 2020-11-10 | 药鼎(北京)国际细胞医学技术有限公司 | 一种治疗肝癌的病毒构建体及其用途和构建方法 |
| CN118853767A (zh) * | 2024-08-22 | 2024-10-29 | 华中科技大学同济医学院附属同济医院 | 一种新型溶瘤腺病毒载体及其构建方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE454445T1 (de) * | 1998-11-10 | 2010-01-15 | Univ North Carolina | Virusvektoren und verfahren für ihre herstellung und verabreichung. |
| AU5464000A (en) * | 1999-06-01 | 2000-12-18 | University Of Washington | Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins |
| US20020045264A1 (en) * | 2000-03-14 | 2002-04-18 | During Matthew J. | Production of chimeric capsid vectors |
| WO2005030261A1 (en) * | 2003-08-28 | 2005-04-07 | Cell Genesys, Inc. | Oncolytic adenoviral vectors encoding gm-csf |
| ES2276623B1 (es) * | 2005-12-12 | 2008-06-01 | Proyecto De Biomedicina Cima, S.L | Nuevos adenovirus recombinantes de replicacion condicionada (crad). |
| US20070292396A1 (en) * | 2006-03-02 | 2007-12-20 | Juan Fueyo | Combination therapy with oncolytic adenovirus |
-
2009
- 2009-12-21 JP JP2011542856A patent/JP2012513209A/ja active Pending
- 2009-12-21 HR HRP20170165TT patent/HRP20170165T1/hr unknown
- 2009-12-21 PT PT97960165T patent/PT2379586T/pt unknown
- 2009-12-21 HU HUE09796016A patent/HUE031689T2/en unknown
- 2009-12-21 SI SI200931586A patent/SI2379586T1/sl unknown
- 2009-12-21 RU RU2011130511/10A patent/RU2520823C2/ru active
- 2009-12-21 DK DK09796016.5T patent/DK2379586T3/en active
- 2009-12-21 AU AU2009332883A patent/AU2009332883B2/en not_active Ceased
- 2009-12-21 SG SG2011046109A patent/SG173432A1/en unknown
- 2009-12-21 WO PCT/FI2009/051025 patent/WO2010072900A1/en not_active Ceased
- 2009-12-21 LT LTEP09796016.5T patent/LT2379586T/lt unknown
- 2009-12-21 EP EP09796016.5A patent/EP2379586B1/en active Active
- 2009-12-21 KR KR1020117016272A patent/KR101761094B1/ko not_active Expired - Fee Related
- 2009-12-21 PL PL09796016T patent/PL2379586T3/pl unknown
- 2009-12-21 CN CN200980151762.9A patent/CN102264760B/zh not_active Expired - Fee Related
- 2009-12-21 BR BRPI0924123A patent/BRPI0924123B8/pt not_active IP Right Cessation
- 2009-12-21 ES ES09796016.5T patent/ES2612889T3/es active Active
- 2009-12-21 CA CA2748180A patent/CA2748180C/en active Active
-
2011
- 2011-06-07 ZA ZA2011/04224A patent/ZA201104224B/en unknown
-
2015
- 2015-08-06 JP JP2015156226A patent/JP6280084B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-27 CY CY20171100126T patent/CY1120039T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2612889T3 (es) | 2017-05-19 |
| JP2016019530A (ja) | 2016-02-04 |
| CA2748180A1 (en) | 2010-07-01 |
| KR20110096579A (ko) | 2011-08-30 |
| BRPI0924123B1 (pt) | 2020-10-20 |
| CA2748180C (en) | 2017-06-20 |
| CY1120039T1 (el) | 2018-12-12 |
| RU2520823C2 (ru) | 2014-06-27 |
| CN102264760B (zh) | 2017-03-22 |
| DK2379586T3 (en) | 2017-02-06 |
| EP2379586A1 (en) | 2011-10-26 |
| HRP20170165T1 (hr) | 2017-04-07 |
| CN102264760A (zh) | 2011-11-30 |
| AU2009332883A1 (en) | 2011-07-07 |
| BRPI0924123B8 (pt) | 2021-05-25 |
| HUE031689T2 (en) | 2017-07-28 |
| KR101761094B1 (ko) | 2017-08-04 |
| AU2009332883B2 (en) | 2015-05-21 |
| JP6280084B2 (ja) | 2018-02-14 |
| SI2379586T1 (sl) | 2017-02-28 |
| SG173432A1 (en) | 2011-09-29 |
| ZA201104224B (en) | 2012-09-26 |
| EP2379586B1 (en) | 2016-11-02 |
| JP2012513209A (ja) | 2012-06-14 |
| WO2010072900A1 (en) | 2010-07-01 |
| RU2011130511A (ru) | 2013-01-27 |
| PT2379586T (pt) | 2017-02-09 |
| PL2379586T3 (pl) | 2017-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201104224B (en) | Oncolytic adenoviral vectors and methods and uses related thereto | |
| ZA201301862B (en) | Oncolytic adenoviral vectors and methods and uses related thereof | |
| IL204538A0 (en) | Poxviral oncolytic vectors | |
| IL204539A0 (en) | Poxviral oncolytic vectors | |
| ZA201004736B (en) | Improved mammalian expression vectors and uses thereof | |
| EP2344648A4 (en) | RECOMBINANT VECTORS | |
| IL210804A (en) | Benzylidenehydrazides and their uses | |
| GB0810912D0 (en) | Vector | |
| GB0820631D0 (en) | Vectors | |
| PT2274422T (pt) | Vetor de expressão | |
| EP2291377A4 (en) | IMIDAZOPYRIMIDINONE AND ITS USES | |
| ZA201005866B (en) | Closterovirus vectors and methods | |
| ZA201103456B (en) | Leukolectins and uses thereof | |
| EP2257308A4 (en) | RECOMBINANT RHINOVIRUS VECTORS | |
| PL2247601T3 (pl) | Tiazopirymidynony i ich zastosowanie | |
| ZA201103960B (en) | An expression vector and processes thereof | |
| FI20095751L (fi) | Ei Ad5 adenoviraaliset vektorit ja niihin liittyvät menetelmät ja käytöt | |
| EP2117588A4 (en) | VIRAL VECTORS AND METHODS OF USE | |
| ZA201100019B (en) | Variant hhip1 protein and methods and uses thereof | |
| GB0810154D0 (en) | Expression vector | |
| GB0702694D0 (en) | Vectors | |
| GB0707069D0 (en) | Methods and uses | |
| GB0800502D0 (en) | Peptides and their uses | |
| GB0816561D0 (en) | Peptides and uses thereof | |
| GB0823425D0 (en) | Vectors |